Status:
COMPLETED
Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome
Lead Sponsor:
UCB Pharma
Conditions:
Restless Legs Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Subjects who meet the diagnosis of idiopathic restless legs syndrome (RLS) based on the 4 cardinal clinical features according to the International Restless Legs Syndrome Study Group (IRLSSG) are allo...
Eligibility Criteria
Inclusion
- Idiopathic restless legs syndrome
Exclusion
- History of sleep disturbances
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
811 Patients enrolled
Trial Details
Trial ID
NCT00135993
Start Date
May 1 2005
End Date
November 1 2006
Last Update
September 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
RTP, North Carolina, United States